Nivolumab is increasingly used in the treatment of melanoma. However, its use is associated with potentially severe side effects and every organ system can be affected. A case is presented where nivolumab therapy resulted in severe diaphragm dysfunction. With nivolumab's increased use, these types of complications may become more common and every clinician should be alerted to its potential presence when a patient on nivolumab treatment presents with dyspnea. Ultrasound is a readily available method to assess for diaphragm dysfunction.
Chaudhari PB. Nivolumab–pearls of evidence. Indian J Med Paediatr Oncol 2017;38:520–525. DOI: 10.4103/ijmpo.ijmpo_193_16.
Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Auré K, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 2018;91(10):985–994. DOI: 10.1212/WNL.0000000000006124.
Bourgeois-Vionet J, Joubert B, Bernard E, Angèle Sia M, Pante V, Fabien N, et al. Nivolumab-induced myositis: a case report and a literature review. J Neurol Sci 2018;387:51–53. DOI: 10.1016/j.jns.2018.01.030.
Moreira A, Loquai C, Pfohler C, Kähler KC, Knauss S, Heppt MV, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 2018;106:12–23. DOI: 10.1016/j.ejca.2018.09.033.
Avinash MP, Nikhil PG, Smita AS, Achhelal PR. Feasibility and utility of ultrasonography in evaluation of diaphragmatic motion and thickness in Indian population. Int J Health Sci 2017;7(5):60–65.
Chacko J, Brar G. Bedside ultrasonography: application in critical care: Part 1. Indian J Crit Care Med 2014;18(5):301–309. DOI: 10.4103/0972-5229.132492.
Banerjee A, Mehrothra G. Comparison of lung ultrasound-based weaning indices with rapid shallow breathing index: are they helpful? Indian J Crit Care Med 2018;22(6):435–440. DOI: 10.4103/ijccm.IJCCM_331_17.
